Skip to main content

NovoCure

NovoCure Ltd is an oncology medical technology company developing Tumor Treating Fields, an electric-field-based cancer therapy. The company designs, manufactures, and markets Optune systems that utilize tuned electric fields to disrupt cancer cell division in glioblastoma and malignant pleural mesothelioma. Main revenue drivers consist of monthly equipment prescription rentals and treatment kit deliveries billed to health insurers and patients. NovoCure serves neuro-oncologists, radiation oncologists, cancer treatment centers, and oncology patients across the United States, Europe, Japan, and Greater China. The company holds a unique pioneer position as the sole commercial developer of electric field cancer therapies globally. Headquartered in St. Helier, Jersey, NovoCure Ltd is listed on the Nasdaq Stock Market.

5 of the funds FundTelligence covers report a position in NovoCure.

Legal name
NovoCure Ltd
Sector
Health Care
Country
Jersey
Funds holding it
5

Funds holding NovoCure

Loading...